Chiesi Returns To Respiratory Roots With Affibody Pact
Upfront And Milestone Payments up to $214m
A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.
